

NLG919, IDO pathway inhibitor

Catalog	Unit
TBI4564-5MG	5 mg
TBI4564-25MG	25 mg

HO.

Product Details

Formal Name: 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

Molecular Formula: C₁₈H₂₂N₂O **Formula Weight:** 282.39 **CAS Number:** 1402836-58-1

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 10 mg/ml)

Storage: -20° C Stability: ≥ 1 year.

Applications

IDO pathway inhibitor

Functions

NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM). It synergizes with chemoradiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma. In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN- γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.

Application Procedures

First dissolved in DMSO (up to 10 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.